Evotec Faces Critical Financial Update Amid Restructuring

Evotec's 2026 forecast signals a tough transition year with revenue and profit declines expected, despite operational wins and deep cost-cutting plans.

Investors in Evotec SE are bracing for a pivotal moment on April 8th. The Hamburg-based biotechnology firm is scheduled to release its complete audited financial statements for 2025 alongside detailed guidance for the current fiscal year. This event will serve as a crucial test, revealing whether the company's extensive corporate overhaul is progressing as planned.

Preliminary Figures Set a Challenging Stage

The pre-released financial data for 2025 paints a mixed picture. Group revenue reached €788 million. However, a significant 16% decline was recorded in the vital Discovery segment, which generated €529 million. The sole bright spot was the Biologics division, Just Evotec Biologics, which saw a 40% surge to €259 million. While adjusted operating profit improved to €41 million, the outlook for 2026 substantially darkens the overall perspective.

Management's forecast for the ongoing year falls short of market expectations. Evotec anticipates revenue in a range of €700 million to €780 million. Even the top end of this guidance sits below the 2025 level. Furthermore, adjusted EBITDA is projected to potentially fall to between zero and €40 million. The company has explicitly labeled 2026 a "transitional year," noting that operational improvements from its restructuring are not expected to take full effect until the latter half.

The "Horizon" Restructuring in Focus

This transition is centered on the operational restructuring program dubbed "Horizon." The plan involves a drastic consolidation of Evotec's physical footprint, reducing sites from 19 to 10. This move will result in the elimination of up to 800 positions, representing nearly one-fifth of the global workforce, alongside a refocusing of research activities into Centers of Excellence. The program aims to deliver annual cost savings of approximately €75 million by the end of 2027. Achieving these savings will come at a price, with restructuring costs estimated at around €100 million in cash through 2028.

Operational Wins Fail to Lift Market Sentiment

Despite the challenging financial forecast, there have been recent positive operational developments. A collaboration bore fruit as Bristol Myers Squibb initiated a Phase 1 study for the CELMoD drug candidate BMS-986506 in clear cell renal cell carcinoma. This milestone, stemming from work on Evotec's AI-driven PanHunter platform, triggered a $10 million payment to the company. Additionally, the Biologics unit secured a BARDA funding award to develop an antibody cocktail against Filovirus diseases like Ebola, featuring an option value of up to $10 million.

These developments have done little to bolster investor confidence in the near term. The market reaction has been muted, with Evotec's share price currently trading approximately 25% below its 200-day moving average. Since the start of the year, the stock has shed nearly a fifth of its value.

Long-Term Targets Provide a Distant North Star

Looking beyond the immediate turbulence, Evotec has established medium-term ambitions to steer its recovery. The company is targeting annual revenue growth of 8% to 12% through 2028, coupled with adjusted EBITDA margins exceeding 20%. By 2030, the goal is to surpass €1 billion in group revenue. The feasibility of these objectives is intrinsically linked to the speed and efficacy of the "Horizon" program's implementation.

Consequently, all eyes will be on management's commentary during the April 8th update, particularly regarding cash utilization and the concrete progress of the restructuring. Further interim updates are scheduled for May 6th and August 13th, 2026, which will offer additional checkpoints on Evotec's path to transformation.